News

Exploring Cost Trends in Investment Management for 2025

Exploring Cost Trends in Investment Management for 2025

Understanding 2025 Investment Management Fee Trends

Callan, a prominent institutional investment consulting firm, has published the findings of its latest study, shedding light on the cost dynamics faced by institutional investors in the investment management landscape. The comprehensive report is based on a thorough analysis of 180 asset pools, showcasing a staggering total of over $772 billion in assets. This study provides crucial insights into the fees associated with investment management, reflecting trends that have evolved since 2010.

Significance of Investment Management Fees

The 2025 Cost of Doing Business Study offers invaluable benchmarks for institutional investors who continually seek to understand the cost-effectiveness of their investment strategies. According to Ivan 'Butch' Cliff, executive vice president and director of research at Callan, the findings reveal that while efforts are being made to reduce fees across various asset classes, a notable shift towards alternative investments is leading to an overall increase in total fund costs for many investors.

Key Findings of the Study

The study highlights several critical findings regarding investment management fees:

  • The average total investment management fees stand at 40 basis points across all types of investors, including nonprofits, public funds, corporate funds, and insurance pools.
  • Asset allocation decisions significantly impact total fund fees. As institutional investors allocate more towards private equity, private credit, and real assets, they are often willing to accept higher fees in exchange for potential diversification and better returns.
  • Nonprofits have seen an increase in average fees by 16% since 2020, contrasting with reductions in fees for corporate (down 17%) and public funds (down 4%).
  • Larger funds typically incur total fees that are 24%–37% higher than smaller funds, primarily due to their increased allocation towards alternative assets.
  • Despite some cost savings achieved through passive strategies and consolidation of managers, these reductions are frequently offset by increased investments in more expensive asset classes.

Longitudinal Data Insights

Callan has been consistently publishing these updates since 1998, with this year's report including data drawn from a proprietary custody fee database. This addition equips institutional investors with deeper insights into their costs and further delineates the types and sizes of funds involved:

  • Nonprofit entities are categorized into two distinct groups based on their asset size: those above and below $1 billion.
  • Corporate funds are analyzed based on their plan types, distinguishing between total return and liability-driven plans, along with asset size classifications similar to nonprofits.
  • Public funds undergo categorization based on asset size into three groups: over $10 billion, over $1 billion, and under $1 billion.
  • For the first time, the study includes insurance pools, broadening the applicability of the data presented.

Broader Implications for Institutional Investors

The findings from Callan's research not only present a snapshot of current fee structures but also guide institutional investors in making informed decisions about their investment strategies. With growing allocations to alternative investments, understanding these fee dynamics becomes essential for optimizing costs and achieving desired returns.

About Callan

Established in 1973, Callan has evolved into an employee-owned investment consulting firm dedicated to providing institutional clients with tailored investment solutions. With assets exceeding $3 trillion under advisement, Callan stands among the largest independent investment consulting firms in the United States. The company prides itself on a client-centered consulting approach, catering to pension plan sponsors, endowments, foundations, independent advisers, and asset managers. Callan maintains a strong presence with six offices nationwide.

Frequently Asked Questions

What is the focus of Callan's 2025 Cost of Doing Business Study?

The study centers on investment management fees incurred by institutional investors and analyzes trends over the years.

How does asset allocation influence investment fees?

Shifts toward alternative investments are leading to higher fees as institutional investors pursue diversification and anticipated returns.

What key trends were identified for different investor types?

Nonprofits have seen an increase in fees, while corporate and public funds have experienced decreases since 2020.

How does the study categorize funds?

Funds are categorized based on type and size, helping investors easily understand their fee structures.

What services does Callan offer?

Callan provides consulting services to a wide range of institutional clients, offering customized investment strategies backed by research and data.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Love Business Group Helps SMEs Navigate Broadband Choices

Updated Category News Views 118

Understanding Broadband Needs for UK SMEs When you're knee-deep in running a small biz in the UK, sorting out your broadband needs can feel like sifting through a thousand-piece puzzle. Enter Love Business Group, getting a nod of recognition for being the SME knight in shining armor. Aimed at businesses of all sizes, they've been pegged by Expert Consumers for helping...

Continue Reading
Sinclair Faces Labor Lawsuit for Break-time Violations

Updated Category News Views 175

Sinclair Television Caught in Labor Law Storm When you think of flaring tempers and boardroom brawls, you typically don't think of your everyday TV station. But right now, Sinclair Television of California, LLC is in the hot seat, accused of playing fast and loose with wage packets—specifically, allegedly denying meal periods and rest breaks that California labor laws...

Continue Reading
Clarins Dazzles Austin with Skin Longevity Event

Updated Category News Views 0

Clarins Takes Austin by Storm Under the vast Austin sky, something remarkable unfolded as Clarins transformed the scene with a flashy rooftop affair that screamed innovation and elegance. They weren’t just showing off fancy bottles of beauty potion; they were stirring the pot, merging science with a splash of high-end glitz. This wasn’t just another product pitch—it...

Continue Reading
RYBREVANT's Promising Results in HNSCC Treatment

Updated Category News Views 138

Impressive Outcomes for RYBREVANT FASPRO in Head and Neck Cancer Tucked away in the endless cycle of drug trials, a glimmer of hope shines through with new data on RYBREVANT FASPRO in treating head and neck squamous cell carcinoma (HNSCC). This science talk might not rattle the ticker tape directly on NYSE:JNJ, but it has all the makings of a game-changer in the oncology...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 393

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
Hims & Hers Faces FTC Heat: Investor Class Action Looms

Updated Category News Views 176

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

Continue Reading
DigitalXForce Shakes Up GRC: AI-Infused X-ROC Launch

Updated Category News Views 98

Turning Risk Management on Its Head Well, here's a company not just tinkering around the edges but flipping the script on Governance, Risk, and Compliance (GRC) with their latest rollout: DigitalXForce and its X-ROC. Yeah, it's yet another acronym to juggle, but don't roll your eyes just yet. This AI-driven beast isn't about occasional boardroom reports. No sir, it's a...

Continue Reading
Borr Drilling's Rig Sinks, Uncertainty Looms Offshore

Updated Category News Views 153

Unexpected Turn of Events at Sea Now here's a gut-punch nobody saw coming. Borr Drilling Limited (NYSE and OSE: BORR) got hit hard when their Prospector 5 drilling rig went under the waves offshore Gabon. This ain't no desk job dilemma; we're talking about a real-life offshore catastrophe. It all went down on October 24, 2026, when the rig experienced a punch through...

Continue Reading
Spooky Dining at CARNE: A Halloween Hit in Oxnard

Updated Category News Views 319

A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...

Continue Reading
Fluence Energy Hits Legal Snag: Investors Called to Act

Updated Category News Views 159

Fluence Energy Faces a Securities Fraud Challenge It's like watching a slow-motion train wreck. Fluence Energy, Inc. (NASDAQ: FLNC) now finds itself in the crosshairs of a securities fraud class action lawsuit. Apparently, someone was playing fast and loose with the truth concerning their financial guidance. The period in question stretches from November 24, 2025, to...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring Schouw & Co.'s Share Buy-Back Strategy for 2025

Updated Category News Views 153

Overview of Schouw & Co.'s Share Buy-Back Program Schouw & Co. has launched an exciting share buy-back initiative, aiming to enhance shareholder value significantly. This program began on May 5, 2025, and is designed to repurchase shares totaling up to DKK 120 million. This investment runs until December 31, 2025, reflecting the company's commitment to its shareholders....

Continue Reading
Schneider National Plans to Reveal Q3 2024 Earnings Soon

Updated Category News Views 45

Schneider National to Report Third Quarter 2024 Earnings Schneider National, Inc. (NYSE: SNDR), a leader in transportation and logistics services, has announced that it will release its third quarter 2024 earnings report on a future date, ahead of the market opening. This announcement is significant as it highlights the company’s continued focus on financial...

Continue Reading
A Closer Look at BioAge Labs: Legal Challenges Ahead

Updated Category News Views 206

Understanding the Legal Landscape of BioAge Labs Investors in BioAge Labs, Inc. have faced new uncertainties as the clinical-stage biopharmaceutical company becomes entangled in legal challenges. As the firm moves forward in its mission to develop innovative therapies aimed at combating metabolic diseases, significant developments have emerged that every investor should...

Continue Reading
Celebrating the Fusion of Science and Cinema at Starmus 2025

Updated Category News Views 202

Fusion of Science and Cinema at Starmus Festival The Starmus Festival is a unique event that intertwines science and art, culminating in extraordinary dialogues and presentations. Recently, renowned director Christopher Nolan was awarded the prestigious Stephen Hawking Medal for Science Communication during this remarkable celebration. This accolade is not just an honor...

Continue Reading
Millicom Takes Steps to Enhance Transparency in Holdings

Updated Category News Views 82

Millicom Takes Steps to Enhance Transparency in Holdings Millicom International Cellular S.A., commonly recognized as Tigo, is making significant strides in open communication and compliance by submitting regulatory notifications regarding major shareholder holdings. This initiative reinforces their commitment to transparency and regulatory excellence in the ever-evolving...

Continue Reading